Zymeworks BC Inc Stock, NASDAQ:ZYME
108 Patriot Drive, Suite A, Middletown, Delaware 19709
Number of Employees: 294
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). ZanidatamabÃ¢â?¬â?¢s unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.